What is Leede Financial’s Estimate for THTX FY2026 Earnings?

Theratechnologies Inc. (NASDAQ:THTX) – Investment analysts at Leede Financial cut their FY2026 earnings per share (EPS) estimates for Theratechnologies in a research note issued on Monday, April 14th. Leede Financial analyst D. Loe now expects that the company will earn $0.12 per share for the year, down from their previous forecast of $0.15. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.20 EPS.

Separately, Research Capitl raised shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Trading Up 3.5 %

Shares of Theratechnologies stock opened at $2.66 on Tuesday. Theratechnologies has a 52 week low of $1.08 and a 52 week high of $3.13. The stock has a market cap of $122.31 million, a PE ratio of -26.60 and a beta of 1.11. The company’s 50-day moving average price is $1.65 and its two-hundred day moving average price is $1.53.

Institutional Investors Weigh In On Theratechnologies

Large investors have recently modified their holdings of the stock. National Bank of Canada FI lifted its holdings in shares of Theratechnologies by 29.4% during the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after purchasing an additional 42,435 shares during the last quarter. Harbour Investments Inc. raised its holdings in Theratechnologies by 20.0% during the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock worth $159,000 after buying an additional 14,655 shares during the period. Wealthspire Advisors LLC lifted its stake in Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after buying an additional 20,000 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in shares of Theratechnologies in the fourth quarter worth about $108,000. Finally, Virtu Financial LLC purchased a new position in shares of Theratechnologies in the fourth quarter worth approximately $40,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.